Management of Neutropenic Toxicity From CDK4/6 Inhibitors

Kristina Frinzi Byers, PharmD, BCOP, discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.

Source: CancerNetwork - January 17, 2019 Category: Cancer & Oncology Authors: Kristina Frinzi Byers, PharmD, BCOP Source Type: news